ProCE Banner Activity

DESTINY-Breast06: Phase III Trial of Trastuzumab Deruxtecan vs Chemotherapy in Previously Treated HR+/HER2-Low or Ultralow MBC

Conference Coverage
Slideset

Results from the phase III DESTINY-Breast06 trial demonstrated clinically meaningful progression-free survival benefit with T-DXd vs single-agent chemotherapy for patients with HR+/HER2-low or HER2-ultralow metastatic breast cancer after progression on endocrine-based therapy with or without targeted therapy.

Released: June 05, 2024

Expiration: June 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.

AstraZeneca

Daiichi Sankyo, Inc.

Novartis Pharmaceuticals Corporation